Search research articles
Contact Us
Filters
Showing results (321-330 of 330) with videos related to
Page
of 33
Sort By:
You have reached the last page of results.
This site can display upto 330 results.
JCO Precision Oncology
|
October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Tareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
The Lancet. Oncology
|
April 10, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2023
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
Jennifer K Litton, Meredith M Regan, Lajos Pusztai, et al.
JCO Precision Oncology
|
January 15, 2026
Olaparib in Patients With Solid Tumors With <i>ATM</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Daniel R Carrizosa, Michael Rothe, Pam K Mangat, et al.
BMJ (Clinical Research Ed.)
|
October 20, 2023
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
Christina Yap, Olga Solovyeva, Johann de Bono, et al.
BMJ (Clinical Research Ed.)
|
October 20, 2023
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance
Christina Yap, Jan Rekowski, Moreno Ursino, et al.
Eclinicalmedicine
|
January 29, 2025
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials
Jan Rekowski, Christina Guo, Olga Solovyeva, et al.
Eclinicalmedicine
|
January 29, 2025
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols
Moreno Ursino, Guillermo Villacampa, Jan Rekowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 19, 2022
Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
Randall A Oyer, Patricia Hurley, Leigh Boehmer, et al.
Journal for Immunotherapy of Cancer
|
March 7, 2025
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Tricia R Cottrell, Michael T Lotze, Alaa Ali, et al.
Page
of 33
Search research articles
Search
Showing results (321-330 of 330) with videos related to
Sort By:
Page
of 33
You have reached the last page of results.
This site can display upto 330 results.
JCO Precision Oncology
|
October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Tareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
The Lancet. Oncology
|
April 10, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2023
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
Jennifer K Litton, Meredith M Regan, Lajos Pusztai, et al.
JCO Precision Oncology
|
January 15, 2026
Olaparib in Patients With Solid Tumors With <i>ATM</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Daniel R Carrizosa, Michael Rothe, Pam K Mangat, et al.
BMJ (Clinical Research Ed.)
|
October 20, 2023
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
Christina Yap, Olga Solovyeva, Johann de Bono, et al.
BMJ (Clinical Research Ed.)
|
October 20, 2023
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance
Christina Yap, Jan Rekowski, Moreno Ursino, et al.
Eclinicalmedicine
|
January 29, 2025
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials
Jan Rekowski, Christina Guo, Olga Solovyeva, et al.
Eclinicalmedicine
|
January 29, 2025
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols
Moreno Ursino, Guillermo Villacampa, Jan Rekowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 19, 2022
Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
Randall A Oyer, Patricia Hurley, Leigh Boehmer, et al.
Journal for Immunotherapy of Cancer
|
March 7, 2025
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Tricia R Cottrell, Michael T Lotze, Alaa Ali, et al.
Page
of 33